Skip to content
value.today
Oxurion NV logo

Oxurion NV

OXUR.BR
$3 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$0 M
For year ending December-2023
Net income
$-21 M
-7321.4% margin
Official annual report (ESEF)
Employees
—

Oxurion NV in brief

Oxurion NV is a listed company in the Biotechnology industry, based in Belgium. Its last known market value was $3 M (January 2024); there is no current figure. In the year to December 2023 it had sales of $0 M and a net loss of $20 M. Its shares trade under the symbol OXUR.BR (EURONEXT).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

Oxurion NV timeline

2 events, 2006–2016
  1. 2006
  2. 🏁
    · approximate
    Incorporated as Oxurion
  3. 2016
  4. •
    Legal Entity Identifier issued
    LEI 549300VWY8KVDFKLDM59 registered.

Events of Oxurion NV from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$34 M$69 M$103 M$137 M20202021202220232024

World rank over time

▼ down 15,229 places since 2020
2020-01-01: #17842#17,84220202021-01-01: #17520#17,52020212022-01-07: #24104#24,10420222024-01-05: #33071#33,0712024

Rank in Belgium: #83 (Jan 2020) · #83 (Jan 2021) · #101 (Jan 2022) · #111 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-7321.4%
Operating margin
-4675.0%
Return on equity
—
Liabilities / assets
301.2%
Revenue growth
-55.6%
R&D / revenue
3857.1%

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2022: revenue $1M, net income $-33M$1MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-21M$0MFY23
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2023$0M-55.6%$-13M$-21M-7321.4%
Dec 2022$1M—$-24M$-33M-5285.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2023$-11M$0M$-11M——
Dec 2022$-20M$0M$-20M——

Annual results

Revenue
$0 M
Operating income
$-13 M
Net income
$-21 M

For year ending December-2023 · source: official annual report (ESEF)

Balance sheet

Total assets
$7 M
Total liabilities
$22 M
Total equity
$-15 M

As of December-2023

Oxurion NV scorecard#

Passes 0 of the 1 checks that could be worked out. Fiscal year 2023.

  • Valuationnot known
  • Growthnot known
  • Profitability0 of 1
  • Financial healthnot known
  • Shareholder returnsnot known

Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Oxurion NV: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in EUR thousands; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Oxurion NV: statements by fiscal year
PeriodTrendFY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue2635951,1282,078
Cost of revenue159513612550
Gross profit104825161,528
Research and development9,98715,98620,69622,053
Selling and marketing——1,2743,252
Operating income−12,110−22,946−28,495−28,620
Interest and finance income414639171468
Interest expense and finance costs7,2709,3791,268408
Provision for credit losses——1,127125
Income before tax−18,966−31,686−29,592−28,560
Income tax3.07.03.00
Net income including minority interests−18,969−31,693−29,595−28,560
Minority interests' share of net income0−8.0−437−548
Net income attributable to shareholders−18,969−31,685−29,158−28,012
Earnings per share, basic-0.01-0.37-0.77-0.75
Earnings per share, diluted-0.01-0.37-0.77-0.75
Balance sheet
Cash and cash equivalents1,6243,4969,74024,511
Inventory05.0——
Current assets2,7407,10613,40927,054
Property, plant and equipment5799120230
Right-of-use (leased) assets1889632521,069
Other intangible assets001,0002,127
Non-current assets3,8104,8875,4677,230
Total assets6,55011,99318,87634,284
Current liabilities19,60712,34910,9137,693
Lease liabilities (non-current)11783344447
Non-current liabilities1294,2279,0711,543
Retained earnings−92,373−73,404−41,719−12,561
Shareholders' equity−13,186−4,583−1,07825,180
Minority interests00−30−132
Total equity−13,186−4,583−1,10825,048
Total liabilities and equity6,55011,99318,87634,284
Cash-flow statement
Share-based compensation3169331,107458
Cash from operating activities−9,765−19,379−26,978−27,079
Capital expenditure−1.0−59−32−119
Cash from investing activities7211140710,064
Debt issued——11,1500
Debt repaid−4,498−3,605——
Shares issued——1,3500
Cash from financing activities7,82213,00111,778−931
Exchange-rate effect on cash1.02322−35
Change in cash−1,871−6,267−14,793−17,946
ReportESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Dec 31, 2023

How Oxurion NV compares in Biotechnology

  • Revenue$0 M · higher than 19% of 647
  • Revenue growth-55.6% · higher than 16% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Oxurion NV🇧🇪$3 M——-55.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2023
Balance sheet:
As of December-2023
Profile updated:
Nov 15, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Oxurion NV? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Oxurion NV's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Oxurion NV? Suggest a correction